These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 28077799)

  • 1. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.
    Du L; Kim JJ; Shen J; Chen B; Dai N
    Oncotarget; 2017 Mar; 8(13):22175-22186. PubMed ID: 28077799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of CDX2, β-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer.
    Laurent C; Svrcek M; Flejou JF; Chenard MP; Duclos B; Freund JN; Reimund JM
    Inflamm Bowel Dis; 2011 Jan; 17(1):232-40. PubMed ID: 20815042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers.
    Alpert L; Yassan L; Poon R; Kadri S; Niu N; Patil SA; Mujacic I; Montes D; Galbo F; Wurst MN; Zhen CJ; Cohen RD; Rubin DT; Pekow JR; Weber CR; Xiao SY; Hart J; Segal J; Setia N
    Hum Pathol; 2019 Jul; 89():44-50. PubMed ID: 31054900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.
    Palacio-Rúa KA; Isaza-Jiménez LF; Ahumada-Rodríguez E; Muñetón-Peña CM
    Rev Gastroenterol Mex; 2014; 79(2):79-89. PubMed ID: 24861525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological, immunohistochemical and molecular features of inflammatory bowel disease associated colorectal carcinoma and associated mucosal lesions - Single institution experience.
    Kamarádová K; Vošmiková H; Rozkošová K; Ryška A; Tachecí I; Laco J
    Pathol Res Pract; 2019 Apr; 215(4):730-737. PubMed ID: 30679085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
    Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
    Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma.
    Javier BM; Yaeger R; Wang L; Sanchez-Vega F; Zehir A; Middha S; Sadowska J; Vakiani E; Shia J; Klimstra D; Ladanyi M; Iacobuzio-Donahue CA; Hechtman JF
    Oncotarget; 2016 Aug; 7(32):50875-50882. PubMed ID: 27248473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.
    He SY; Li YC; Wang Y; Peng HL; Zhou CL; Zhang CM; Chen SL; Yin JF; Lin M
    World J Gastroenterol; 2022 Jul; 28(25):2920-2936. PubMed ID: 35978873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients.
    Chang YS; Chang SJ; Yeh KT; Lin TH; Chang JG
    Onkologie; 2013; 36(12):719-24. PubMed ID: 24356563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysplasia and colorectal cancer in inflammatory bowel disease: a result of inflammation or an intrinsic risk?
    Breynaert C; Vermeire S; Rutgeerts P; Van Assche G
    Acta Gastroenterol Belg; 2008; 71(4):367-72. PubMed ID: 19317276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors.
    Sakai E; Ohata K; Chiba H; Matsuhashi N; Doi N; Fukushima J; Endo H; Takahashi H; Tsuji S; Yagi K; Matsusaka K; Aburatani H; Nakajima A; Kaneda A
    Int J Cancer; 2014 Oct; 135(7):1586-95. PubMed ID: 24590867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mathematical modeling the order of driver gene mutations in colorectal cancer.
    Li L; Hu Y; Xu Y; Tang S
    PLoS Comput Biol; 2023 Jun; 19(6):e1011225. PubMed ID: 37368936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of the clinicopathological characteristics and survival outcomes of inflammatory bowel disease associated colorectal cancer.
    Reynolds IS; O'Toole A; Deasy J; McNamara DA; Burke JP
    Int J Colorectal Dis; 2017 Apr; 32(4):443-451. PubMed ID: 28078433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation.
    Hartman DJ; Binion DG; Regueiro MD; Miller C; Herbst C; Pai RK
    Inflamm Bowel Dis; 2018 Jul; 24(8):1780-1790. PubMed ID: 29788391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Profiling of Colorectal Carcinomas of Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.
    de Krijger M; Carvalho B; Rausch C; Bolijn AS; Delis-van Diemen PM; Tijssen M; van Engeland M; Mostafavi N; Bogie RMM; Dekker E; Masclee AAM; Verheij J; Meijer GA; Ponsioen CY
    Inflamm Bowel Dis; 2022 Sep; 28(9):1309-1320. PubMed ID: 35554535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports.
    Okada S; Hata K; Kawai K; Yamamoto Y; Tanaka T; Nishikawa T; Sasaki K; Kaneko M; Emoto S; Murono K; Nozawa H
    Medicine (Baltimore); 2019 Mar; 98(12):e14781. PubMed ID: 30896620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
    Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
    Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.